HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients

Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma (HCC); a Multi-center, Interventional, Non-randomized, Non-comparative, Open Label, Early Phase II Study: HEPAR Primary

Patients with hepatocellular carcinoma often die from intrahepatic disease since current treatment options are generally limited. Local treatment using holmium radioembolization could offer an effective treatment and a more personal approach than yttrium radioembolization (standard-of-care) as holmium has more imaging options.

Study Overview

• Status: Completed
• Conditions: Hepatocellular Carcinoma; Hepatocellular Carcinoma Non-resectable
• Intervention / Treatment: Device: Holmium-166 radioembolization

Detailed Description

Primary objective:

• To establish the safety and toxicity profile of holmium radioembolization in patients with hepatocellular carcinoma.

Secondary objectives:

• To evaluate efficacy of holmium radioembolization in hepatocellular carcinoma without curative treatment options in a non-comparative phase II study.
• To evaluate tumor marker response.
• To evaluate Quality of Life (QoL).
• To evaluate biodistribution / dosimetry.
• To evaluate hepatic function.

Study design: Multi-center, interventional, treatment, non-randomized, open label, non-comparative, early phase II study. The study is a collaboration between UMC Utrecht and Erasmus MC Rotterdam. Recruitment and treatment of patients will take place in both centers.

Intervention: Holmium radioembolization will be performed via a catheter during angiography.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 2

Contacts and Locations

Study Locations

• Netherlands
  • Rotterdam, Netherlands, 3015CN
    • Erasmus Medical Center
  • Utrecht, Netherlands, 3584 CX
    • University Medical Center Utrecht

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients must have given written informed consent.
• Female or male aged 18 years and over.
• Diagnosis of HCC established according to the Netherlands HCC guideline criteria (in line with American AASLD criteria): nodule >1 cm in a patient at risk for HCC, with combination of arterial hypervascularity and venous or delayed phase wash-out on multiphase CT-scan or MRI-scan.2, 4 LR-5 and LR- 4 based on Liver Imaging Reporting and Data System can be included based on discretion of the principal investigator.I
• No curative treatment options (resection, transplant, or in case of solitary tumor <5 cm, RFA).
• Life expectancy of at least 6 months.
• ECOG Performance status 0-1 (Table 2).
• Liver-dominant disease (maximum 5 lung nodules all ≤1.0 cm and mesenteric or portal lymph nodes all ≤2.0 cm are accepted).
• Child-Pugh class A5-6 or B7.
• At least one measurable liver lesion according to the modified RECIST criteria.21
• Negative pregnancy test for women of childbearing potential. Female patients of child-bearing potential should use an highly effective acceptable method of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal ligation) or should be more than 1 year postmenopausal or surgically sterile during their participation in this study (from the time they sign the consent form), to prevent pregnancy.

Exclusion Criteria:

• Evidence of significant extrahepatic disease (MRI-scan liver and multiphase abdominal CT as well as a thoracic CT are routinely performed at screening).
• Radiation therapy within the last 4 weeks before the start of study therapy.
• Previous or current treatment with RE. Previous treatment with TACE, surgery, RFA, and previous or current treatment with sorafenib are allowed.
• Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy.
• Serum bilirubin >34.2 micromole/L (2 mg/dL).
• Glomerular filtration rate <35 ml/min, determined according to the Modification of Diet in Renal Disease formula.
• Non-correctable INR >1.5 in case of femoral approach (as opposed to radial).
• Leukocytes <2 109/l and/or platelet count <50 109/l.
• Significant cardiac event (e.g. myocardial infarction, superior vena cava (SVC) syndrome, New York Heart Association (NYHA) classification of heart disease ≥2 within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
• Pregnancy or breastfeeding.
• Patients suffering from psychic disorders that make a comprehensive judgment impossible, such as psychosis, hallucinations and/or depression.
• Patients who are declared incapacitated.
• Previous enrollment in the present study.
• Male patients who are not surgically sterile or do not use an acceptable method of contraception during their participation in this study (from the time they sign the consent form) to prevent pregnancy in a partner.
• Evidence of untreated, clinically significant grade 3 portal hypertension (i.e. large varices at oesophago-gastro-duodenoscopy). In these cases, therapy with non-selective beta blocker (propranolol) or rubber band ligation should be instituted according to accepted guidelines. In case of small varices, prophylactic propranolol is advised.
• Portal vein thrombosis (tumor and/or bland) of the main branch (diagnosed on contrast enhanced transaxial images). Involvement of the right or left portal vein branches and more distal is accepted.
• Untreated active hepatitis. In case of detectable viral HBV load, treatment with a nucleos(t)ide analog such as entecavir or tenofovir should be instituted.
• Transjugular intrahepatic portosystemic shunt (TIPS).
• Body weight over 150 kg (because of maximum table load).
• Severe allergy for intravenous contrast used (Visipaque®)(because of CT evaluation, pre-treatment angiography and treatment angiography).
• Lung shunt >30 Gy, as calculated using scout dose SPECT/CT.
• Uncorrectable extrahepatic deposition of scout dose activity. Activity in the falciform ligament, portal lymph nodes and gallbladder is accepted.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Holmium-166 radioembolization

Device: Holmium-166 radioembolization; An intra-arterial radioembolization procedure will be performed. The hepatic artery catheter is inserted via the femoral or radial artery under x-ray guidance by a trained interventional radiologist. The radiologist must repeatedly check the position of the catheter during the procedure to ensure it remains correctly sited and that reflux of the QuiremSpheres® into other organs does not occur. This is performed by injecting contrast medium. At the conclusion of the procedure, the catheter is removed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety, expressed as the rate of unacceptable toxicity.	Safety, expressed as the rate of unacceptable toxicity, which is the occurrence of RE-induced liver disease, defined as a total bilirubin increase grade 3 or higher according to the CTCAE version 4.03, in combination with ascites and low albumin, in the absence of disease progression	Up to 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor response based on radiologic assessment of MRI scans using mRECIST	Tumor response based on radiologic assessment of MRI scans using mRECIST	Up to 6 months
Changes in tumor marker alpha-fetoprotein	Changes in tumor marker alpha-fetoprotein	Up to 6 months
Quality of Life (QoL) using EORTC C30	Quality of Life (QoL) using EORTC C30	Up to 6 months
Quality of Life (QoL) using EORTC HCC18	Quality of Life (QoL) using EORTC HCC18	Up to 6 months
Quality of Life (QoL) using BPI-SF	Quality of Life (QoL) using BPI-SF	Up to 6 months
Biodistribution/dosimetry based on quantitative assessment of MRI scans	Biodistribution/dosimetry based on quantitative assessment of MRI scans	Up to 6 months
Changes in hepatic function as determined by hepatobiliary scintigraphy	Changes in hepatic function as determined by hepatobiliary scintigraphy	Up to 3 months

Collaborators and Investigators

• Sponsor: UMC Utrecht
• Collaborators: Erasmus Medical Center; Dutch Cancer Society; Quirem Medical B.V.
• Investigators: Principal Investigator: Marnix G. Lam, MD, PhD, UMC Utrecht

Study record dates

Study Major Dates

• Study Start (Actual): August 21, 2017
• Primary Completion (Actual): January 1, 2020
• Study Completion (Actual): August 1, 2021

Study Registration Dates

• First Submitted: November 21, 2017
• First Submitted That Met QC Criteria: December 19, 2017
• First Posted (Actual): December 20, 2017

Study Record Updates

• Last Update Posted (Actual): November 8, 2022
• Last Update Submitted That Met QC Criteria: November 7, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular
• Other Study ID Numbers: NL52338.041.17

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No